NEWS & MEDIA
Read our recent announcements
Press
November 18, 2026
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Read more

No results found

Try a different search, category, or year.
Publications
November 18, 2026
IAM-C1, a Potent and Selective Dual CDK2/CDK4 Inhibitor, Demonstrates Robust Antitumor Activity and a Favorable Preclinical Tolerability Profile
Read more
IAM217 scientific poster for ENA 2026
Publications
November 18, 2026
IAM217: a Novel, Brain-penetrant KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer
Read more
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Press
November 16, 2026
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Read more
Press
November 9, 2026
Iambic to participate in Jefferies Global Healthcare Conference
Read more
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Read more
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publications
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Read more
Iambic Announces Pricing of Initial Public Offering
Press
October 14, 2026
Iambic Announces Pricing of Initial Public Offering
Read more
Press
October 5, 2026
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Read more
Press
September 21, 2026
Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & Development
Read more
Press
November 18, 2026
Iambic Presents Preclinical Data for CDK2/4 Inhibitor IAM-C1 and Brain-Penetrant KIF18A Inhibitor IAM217 at 2026 EORTC-NCI-AACR Symposium
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Press
November 16, 2026
Iambic Provides Business Updates and Third Quarter 2026 Financial Results
Press
November 9, 2026
Iambic to participate in Jefferies Global Healthcare Conference
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026
Press
October 26, 2026
Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Iambic Announces Pricing of Initial Public Offering
Press
October 14, 2026
Iambic Announces Pricing of Initial Public Offering
Press
October 5, 2026
Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate
Publications
November 18, 2026
IAM-C1, a Potent and Selective Dual CDK2/CDK4 Inhibitor, Demonstrates Robust Antitumor Activity and a Favorable Preclinical Tolerability Profile
IAM217 scientific poster for ENA 2026
Publications
November 18, 2026
IAM217: a Novel, Brain-penetrant KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publications
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publications
December 7, 2025
Scaling Multi-Modal and Multi-Task Transformers for Small Molecule Drug Discovery
Publications
December 3, 2025
San Diego NeuralPLexer3: Accurate Biomolecular Complex Structure Prediction with Flow Models
Publications
October 19, 2025
A Phase 1/1b Study of IAM1363, a selective and brain penetrant HER2 inhibitor in participants (pts) with advanced cancers harboring HER2 alterations (ESMO 2025)
Publications
September 9, 2025
IAM1363 is a Potent, Selective, and Irreversible HER2 and Pan-HER2 Mutant Small Molecule Inhibitor for the Treatment of HER2-Driven NSCLC
Publications
May 5, 2025
Enchant v2: Pushing the Boundaries of Predictive Drug Discovery
Publications
April 29, 2025
A Novel KIF18A Inhibitor for Targeting Chromosomal Instability in Cancer (AACR 2025 Poster)
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Publications
October 23, 2026
Safety and Activity of IAM1363, a CNS-penetrant HER2 TKI in Participants with HER2 Altered Advanced Cancers
Presentations
January 13, 2026
JPM Healthcare Conference 2026 Company Presentation
Presentations
October 30, 2025
Promise & Reality: Decoding AI’s Impact On Drug Development
Presentations
October 28, 2025
From Models to Medicines: Delivering on the Promise of AI-Driven Drug Discovery
Presentations
September 23, 2025
Enchant: A Multi-Modal Transformer Model to Break Down the Data Wall between Preclinical and Clinical Research and Development
Presentations
September 22, 2025
Leveraging AI/ML to Engineer Next-Generation HER2 Inhibitors with Enhanced Selectivity and Brain Penetrance
Presentations
September 10, 2025
Predictive Drug Discovery with Enchant v2
Presentations
August 18, 2025
Iambic will present new preclinical NSCLC data for IAM1363, a potent Type II HER2 inhibitor, at #WCLC25
Presentations
August 11, 2025
Fireside chat at the KeyBanc Capital Markets Technology Leadership Forum
For media requests
Contact our communications team at media@iambic.ai
Contact us
No results found